Aura Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Aura Biosciences, Inc. (AURA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $5.37 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-11
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $5.00, a 14.97% decline year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $5.88, a 0.34% decline year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $5.90, a 21.54% decline year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $7.52, a 37.23% decline year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $5.51, a 8.01% decline from fiscal 2024.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $5.99, a 20.13% decline from fiscal 2023.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $7.50, a 30.49% decline from fiscal 2022.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $10.79, a 84.76% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.37 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $5.00 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $5.51 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $5.54 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $5.57 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | $5.88 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | $5.99 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $5.85 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $5.84 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | $5.90 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $7.50 10-K · filed 2025-03-24 | |||
| 2023-09-30 | $7.81 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $7.66 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $7.52 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $10.79 10-K · filed 2024-03-27 | |||
| 2022-09-30 | $11.09 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $11.56 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | $11.98 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $5.84 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $3.97 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $3.56 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $3.56 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $2.74 10-K · filed 2022-03-23 | |||
| 2020-09-30 | $2.74 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |